Omics Collaboration DNA Link already partners with SomaLogic to offer the SomaScan 7,000-plex proteomics platform to its customers, highlighting a strong cross-sell opportunity for proteomics-enabled multi-omics research. This creates a pathway to jointly market integrated genomics-proteomics diagnostics to CROs, hospitals, and pharma customers. Potential sales angles include multi-omics data packages, joint marketing, and data integration services.

Diagnostics Expansion The company is developing cancer diagnostic systems and disease markers using DNA chip and next-generation sequencing, signaling demand for end-to-end diagnostic development, regulatory support, and commercial deployment. Sales opportunities include assay development, clinical validation, companion diagnostic partnerships, and scalable lab services or kit offerings for oncology diagnostics.

Global Partnerships With international collaborations in place, there is potential to accelerate geographic expansion through co-development, distribution agreements, and CRO partnerships, especially between Korea and Western markets. Target customers include pharma, biotech, and academic centers seeking access to Asia-Pacific patient data, trial sites, or co-development capabilities.

Data Security Rapid whole-genome analysis generates substantial data and compute needs; there is a clear need for secure data management, scalable analytics pipelines, and regulatory-compliant data sharing solutions. Sales opportunities include cloud-based bioinformatics platforms, data storage and processing services, and customized IT solutions for genomic workflows.

Growth Readiness As a mid-sized biotech with notable revenue and a focused R&D profile, DNA Link could benefit from scalable software, automation, and service contracts to sustain growth. Potential offers include LIMS and workflow software integration, AI-assisted analysis tools, automated reporting, and managed services to accelerate research timelines for oncology and other diseases.